CGC
NASDAQ
CA
Canopy Growth Corporation - Common Shares
$1.00
▲ +$0.03
(+2.67%)
Vol 6.9M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$574.8M
ROE
-67.0%
Margin
-138.5%
D/E
35.23
Beta
2.99
52W
$1–$4
Wall Street Consensus
13 analysts · Apr 20260
Strong Buy
1
Buy
5
Hold
5
Sell
2
Strong Sell
7.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.05 | $-0.18 | $-0.13 |
| Sep 2025 | $-0.16 | $-0.01 | +$0.15 |
| Jun 2025 | $-0.24 | $-0.22 | +$0.02 |
| Mar 2025 | $-0.48 | $-1.47 | $-0.99 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $74.8M | $65.0M | $72.1M | $66.7M | $74.5M |
| Net Income | — | -$121.9M | -$220.8M | -$41.5M | -$1.6M | -$62.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -98.7% | -112.8% | -98.7% | -98.7% | -67.0% | -67.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -57.6% | -222.3% | -186.4% | -186.4% | -138.5% | -138.5% |
| Gross Margin | 25.0% | 30.3% | 27.8% | 27.8% | 27.5% | 27.5% |
| D/E Ratio | 67.04 | 66.76 | 67.04 | 67.04 | 35.23 | 35.23 |
| Current Ratio | 3.07 | 3.12 | 3.07 | 3.07 | 5.50 | 5.50 |
Key Ratios
ROA (TTM)
-38.1%
P/S (TTM)
2.06
P/B
0.5
EPS (TTM)
$-2.77
CF/Share
$-1.81
Rev Growth 3Y
-19.2%
52W High
$4.41
52W Low
$1.09
$1.09
52-Week Range
$4.41
Financial Health
Free Cash Flow
-$19.1M
Net Debt
-$116.2M
Cash
$371.3M
Total Debt
$255.1M
As of Dec 31, 2025
How does CGC compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CGC valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.1
▼
58%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
0.5
▼
76%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CGC profitability vs Pharmaceuticals peers
ROE
-67.0%
▼
23%
below
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
-138.5%
▼
192%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
27.5%
▼
60%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-38.1%
▼
2%
below
peers
(-37.4%)
vs Peers
vs Industry
In line
CGC financial health vs Pharmaceuticals peers
D/E ratio
35.2
▲
2188%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
5.5
▲
64%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
3.0
▲
218%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
CGC fundamentals radar
CGC
Peer median
Industry
CGC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio